Leylah Drusbosky

Leylah Drusbosky

Auto-generated profile, based on publicly available information

Leylah Drusbosky

Guardant Health, Redwood City, California

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MNMarcelo V. Negrao
Marcelo V. Negrao
HAHaniel A. Araujo
Haniel A. Araujo
GLGiuseppe Lamberti
Giuseppe Lamberti
ACAlissa J. Cooper
Alissa J. Cooper
NANeal S. Akhave
Neal S. Akhave
FSFerdinandos Skoulidis
Ferdinandos Skoulidis
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 patients with non–small cell lung cancer (NSCLC), we identified and validated coalterations in KEAP1, SMARCA4, and CDKN2A as major independent determinants of inferior clinical outcomes with KRASG12Ci monotherapy. Collectively, comutations in these three tumor suppressor genes segregated patients into distinct prognostic subgroups and captured ∼50% of those with early disease progression (progression-free survival ≤3 months) with KRASG12Ci. Pathway-level integration of less prevalent coalterations in functionally related genes nominated PI3K/AKT/MTOR pathway and additional baseline RAS gene alterations, including amplifications, as candidate drivers of inferior outcomes with KRASG12Ci, and revealed a possible association between defective DNA damage response/repair and improved KRASG12Ci efficacy. Our findings propose a framework for patient stratification and clinical outcome prediction in KRASG12C-mutant NSCLC that can inform rational selection and appropriate tailoring of emerging combination therapies. Significance: In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose a framework for patient stratification and treatment personalization based on the comutational status of individual tumors. See related commentary by Heng et al., p. 1513. This article is highlighted in the In This Issue feature, p. 1501

17 October 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PPPamela Soberanis Pina
Pamela Soberanis Pina
KCKeelia Clemens
Keelia Clemens
ABAdrian Bubie
Adrian Bubie
BGBrooke Grant
Brooke Grant
GHGinger Haynes
Ginger Haynes
SLStephanie Lheureux
Stephanie Lheureux
Purpose: ctDNA is a novel technique extensively studied in solid tumors, although not currently well defined in endometrial cancer. Experimental Design: A de-identified retrospective analysis of 1,988 patients with advanced/recurrent endometrial cancer was performed. In addition, an analysis of a real-world evidence cohort was completed (n = 1,266). Patients underwent ctDNA testing using Guardant360 during routine clinical care. The objective was to describe and assess molecular landscape using ctDNA. Results: Among 1,988 ctDNA samples, at least one somatic alteration was detected in 91.6% (n = 1,821). Most frequently altered genes were TP53 (64%), PIK3CA (29%), PTEN (25%), ARID1A (20%), and KRAS (14%). Overall, 18.5% had amplifications, with the majority identified in CCNE1 (40.9%), PIK3CA (22%), and EGFR (19.3%). From the real-world evidence cohort, those with TP53 mutations had a worse overall survival (OS) versus those without TP53 mutations (P = 0.02) and those with TP53 comutations had an inferior OS in comparison with TP53-mutated only (P = 0.016). Amongst these, patients with a PIK3CA comutation (P = 0.012) and CCNE1 amplification (P = 0.01) had an inferior OS compared with those with only TP53 mutations. Fifty-seven patients with newly diagnosed endometrial cancer had at least two serial ctDNA samples showing evolution in detected variants compared with baseline samples, with TP53 being the most frequent change. Conclusions: This study is one of the largest cohorts of ctDNA currently reported in endometrial cancer. The presence of TP53 mutation and other comutations detected by ctDNA have a negative effect on outcomes. This report suggests that ctDNA analysis is feasible and could become a useful biomarker for endometrial cancer.

10 January 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
GBGehan Botrus
Gehan Botrus
Pedro Luiz Serrano Uson JuniorPedro Luiz Serrano Uson Junior
Pedro Luiz Serrano Uson Junior
PRPuneet Raman
Puneet Raman
AKAdrienne E. Kaufman
Adrienne E. Kaufman
HKHeidi Kosiorek
Heidi Kosiorek
TBTanios Bekaii-Saab
Tanios Bekaii-Saab
Background: Plasma-based circulating cell-free tumor DNA (ctDNA) genomic profiling by next-generation sequencing (NGS)is an emerging diagnostic tool for pancreatic cancer (PC). The impact of detected genomic alterations and variant allele fraction (VAF) in tumor response to systemic treatments and outcomes is under investigation.Methods: Patients with advanced PC who had ctDNA profiled at time of initial diagnosis were retrospectively evaluated. We considered the somatic alteration with the highest VAF as the dominant clone allele frequency (DCAF). ctDNA NGS results were related to clinical demographics, progression-free survival (PFS) and overall survival (OS).Results: A total of 104 patients were evaluated. Somatic alterations were detected in 84.6% of the patients. Patients with ≥ 2 detectable genomic alterations had worse median PFS (p < 0.001) and worse median OS (p = 0.001). KRAS was associated with disease progression to systemic treatments (80.4% vs 19.6%, p = 0.006), worse median PFS (p < 0.001) and worse median OS (p = 0.002). TP53 was associated with worse median PFS (p = 0.02) and worse median OS (p = 0.001). The median DCAF was 0.45% (range 0-55%). DCAF >0.45% was associated with worse median PFS (p<0.0001) and median OS (p=0.0003). Patients that achieved clearance of KRAS had better PFS (p=0.047), while patients that achieved clearance of TP53 had better PFS (p=0.0056) and OS (p=0.037).Conclusions: Initial detection of ctDNA in advanced PC can identify somatic alterations that may help predict clinical outcomes. The dynamics of ctDNA are prognostic of outcomes and should be evaluated in prospective studies.

1 March 2021 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
DRDeepak Ravindranathan
Deepak Ravindranathan
GRGreta Anne Russler
Greta Anne Russler
LYLauren Yantorni
Lauren Yantorni
LDLeylah M. Drusbosky
Leylah M. Drusbosky
MBMehmet Bilen
Mehmet Bilen
Pembrolizumab has been approved by the US Food and Drug Administration for the treatment of metastatic or unresectable solid tumors that are microsatellite instability-high (MSI-H) or mismatch repair deficient. Blood-based circulating tumor DNA (ctDNA) assays have been validated to identify tumors with MSI-H status without the need for tissue biopsy. We report 2 patients with metastatic castration-resistant prostate cancer (mCRPC) who had prior treatment with multiple lines of therapy and underwent ctDNA testing, which detected MSI-H status. Both patients were treated with pembrolizumab, resulting in an excellent clinical response measured with liquid biopsies before and after initiation of therapy, which demonstrated a significant reduction in somatic-variant allele frequency in addition to a decrease in prostate serum antigen levels.

16 December 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
MWMichael White
Michael White
MZMohammad A. Zeineddine
Mohammad A. Zeineddine
EFEleanor A. Fallon
Eleanor A. Fallon
FZFadl A. Zeineddine
Fadl A. Zeineddine
JDJulia Dansby
Julia Dansby
JSJohn Paul Ying-Ching Shen
John Paul Ying-Ching Shen
Purpose: Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of appendiceal adenocarcinoma relative to common tumors. Experimental Design: We analyzed molecular data for patients within the Guardant Health database with appendix cancer (n = 718). We then identified patients with appendiceal adenocarcinoma at our institution (from October 2004–September 2022) for whom ctDNA mutation profiling (liquid biopsy) was performed (n = 168) and extracted clinicopathologic and outcomes data. Of these 168 patients, 57 also had tissue-based tumor mutational profiling, allowing for evaluation of concordance between liquid and tissue assays. Results: The mutational landscape of ctDNA in appendiceal adenocarcinoma is distinct from tissue-based sequencing, with TP53 being the most frequently mutated (46%). Relative to other tumors, appendiceal adenocarcinoma seems less likely to shed ctDNA, with only 38% of patients with metastatic appendiceal adenocarcinoma having detectable ctDNA (OR = 0.26; P < 0.0001 relative to colorectal cancer). When detectable, the median variant allele frequency was significantly lower in appendiceal adenocarcinoma (0.4% vs. 1.3% for colorectal cancer; P ≤ 0.001). High-grade, signet ring, or colonic-type histology, metastatic spread beyond the peritoneum, and TP53 mutation were associated with detectable ctDNA. With respect to clinical translation, patients with detectable ctDNA had worse overall survival (HR = 2.32; P = 0.048). In the Guardant Health cohort, actionable mutations were found in 93 patients (13.0%). Conclusions: Although metastatic appendiceal adenocarcinoma tumors are less likely to shed tumor DNA into the blood relative to colorectal cancer, ctDNA profiling in appendiceal adenocarcinoma has clinical utility.

12 June 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
MGMohamed Alaa Gouda
Mohamed Alaa Gouda
FJFilip Janku
Filip Janku
YYYing Yuan
Ying Yuan
LDLeylah M. Drusbosky
Leylah M. Drusbosky
ACAlice Chen
Alice Chen
FMFunda Meric-Bernstam
Funda Meric-Bernstam
Purpose: Liquid biopsies with circulating tumor DNA (ctDNA) analysis are increasingly being utilized as a noninvasive approach to identify actionable genomic alterations in advanced/metastatic cancers. In this study, we report the correlation between ctDNA analysis of plasma samples collected from patients enrolled in the NCI-MATCH trial and tumor tissue–based sequencing. Experimental Design: We analyzed plasma samples collected from patients enrolled on 16 subprotocols of NCI-MATCH who had plasma samples collected within 90 days before starting treatment. Concordance was defined as the detection of the same gene alteration leading to patient enrollment in NCI-MATCH in both tissue and plasma. Results: We included 300 patients who were enrolled in NCI-MATCH. Most patients (81%, n = 243) were enrolled based on central tissue testing and had contemporaneous tissue and plasma samples. The tissue alteration of interest was detected in the plasma of 81.1% (n = 197) of patients. Lower rates of detection of the tissue alteration of interest were observed in samples from 57 patients who were enrolled based on outside designated laboratory testing (56.1%, n = 32) and had noncontemporaneous tissue and plasma samples. Variations in concordance rates were observed with different alteration types, by maximum plasma variant allele frequency, and based on tumor biopsy site. Conclusions: The tumor tissue alteration of interest was detected in the plasma of 81% of patients who were enrolled in the NCI-MATCH trial based on central tissue testing and had contemporaneous tissue and plasma samples. This suggests a potential role for liquid biopsy in patient enrollment in trials evaluating biomarker-driven anticancer therapies.